ArticleJournal for immunotherapy of cancer2026

Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer.

Lin Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.